Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR New Investigator

McMaster University

$300,000.00

Combinatorial Creation of Targeted Therapeutics for Breast Cancer

EF 2010-11

Résumé
Natural products have long been a source of innovative anticancer therapeutic agents. With respect to breast cancer, natural products and chemical derivatives of them constitute a large majority of clinically used chemotherapeutic agents. One class of natural drugs known as depsipeptides have been the focus of much attention in recent times for their capacity to kill breast cancer cells and act on targets that would lead to less toxicity. Two of the targets of these natural drugs, BclXl and GRP78, are known to be upregulated in breast cancer cells leading to cancer cells ability to resist programmed cell death (apoptosis). The focus of this grant is to harness, and strategically re-engineer, the natural biosynthetic enzymes for making anticancer depsipeptides to create improved chemical analogs for breast cancer therapeutic development. We have designed a strategy to combine structural features of distinct anticancer depsipeptides to make possible new chemotherapeutic agents that have a much greater capacity to kill breast cancer cells.
Programme
CIHR New Investigator
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
213620
Name
Magarvey Nathan A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
New Investigators A
Projecttitle
Combinatorial Creation of Targeted Therapeutics for Breast Cancer
Programtype2
Salary Programs
Orgnameinp2
McMaster University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
CIHR New Investigator
Keyworddelim
Apoptosis; Bclxl And Grp; Bioactive Small Molecules; Breast Cancer; Depsipeptide; Natural Products; Nonribosomal Peptides; Selective Therapeutics
Abstract
Natural products have long been a source of innovative anticancer therapeutic agents. With respect to breast cancer, natural products and chemical derivatives of them constitute a large majority of clinically used chemotherapeutic agents. One class of natural drugs known as depsipeptides have been the focus of much attention in recent times for their capacity to kill breast cancer cells and act on targets that would lead to less toxicity. Two of the targets of these natural drugs, BclXl and GRP78, are known to be upregulated in breast cancer cells leading to cancer cells ability to resist programmed cell death (apoptosis). The focus of this grant is to harness, and strategically re-engineer, the natural biosynthetic enzymes for making anticancer depsipeptides to create improved chemical analogs for breast cancer therapeutic development. We have designed a strategy to combine structural features of distinct anticancer depsipeptides to make possible new chemotherapeutic agents that have a much greater capacity to kill breast cancer cells.
Competitiondate
201009
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Magarvey, Nathan A
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~